Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vortioxetine for MDD and Cognitive Dysfunction
NCT02749721Phase 4Completed
- Sponsor
- Rush University Medical Center
- Start
- Dec 2016
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of vortioxetine in major depressive disorder (MDD), sponsored by Rush University Medical Center. Primary endpoints: Montgomery and Asberg Depression Rating Scale at 8 weeks and Digital Symbol Substitution Test at 8 weeks. Started Dec 2016; status: completed.
02
Drugs
vortioxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02749721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02749721.